The company plans to submit its 650- to 700-gene panel, which will include microsatellite instability testing, to the FDA for approval as a companion diagnostic.

Researchers profiled cancer gene mutations, expression, protein patterns, and other features in 23 recurrent or metastatic cases of olfactory neuroblastoma.

The firm has been developing several new tests that are based on its ADAPT aptamer profiling technology.

The Irving, Texas-based company claims that three of Foundation Medicine's cancer molecular profiling tests infringe five of its US patents.

The study will perform next-generation sequencing on archival tumor tissue from 200 individuals with metastatic urothelial cancer.

The companies will perform tumor profiling to identify patients with genetic abnormalities that could make them eligible for treatment in the NCI study.

There are now 100 sites in the US participating in the basket study, and soon trials with similar approaches will be available in Canada and 13 other countries.

Though considered potential antibody alternatives, these reagents are more likely to succeed in new applications for which conventional tools are poorly suited.

Caris will be on the lookout for pancreatic cancer patients with low DNA mismatch repair protein expression. 

There was a lot of growth in the precision medicine field in the past year, and some experts believe the FDA's decision to hold off on regulating LDTs could spur more innovation.


An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.